Table 2 Summary of main findings
Key GAVI strategy, policy and programme pillar | EQUITY OF OPPORTUNITY | EQUITY OF OUTCOME (Intermediate) | EQUITY OF OUTCOME (Final) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Between-country equity comparing | Between-country equity comparing | Within-country equity comparing | Between-country equity comparing | ||||||||
(i) access to new/underutilized vaccines: | (ii) access to GAVI resources: | (iii) utilization of immunization services: | (iii) utilization of immunization services | (iv) VPD burden among: | |||||||
GAVI phase of operations | GAVI and non-GAVI countries | Individual GAVI countries | GAVI and non-GAVI countries | Individual GAVI countries | GAVI and non-GAVI countries | Individual GAVI countries | Geography (between district) | Socio-economic status | Gender | GAVI and non-GAVI countries | Individual GAVI countries |
1. Overarching strategy and workplans | |||||||||||
Phase I | ++ | -(+) | ++ | -(+) | +(+) | +(+) | ++ | -(+) | ++ | + | + |
Phase II | ++ | -(+) | ++ | -(+) | +(+) | +(+) | ++ | -(+) | -- | -(+) | -(+) |
Phase III | + | -(+) | + | -(+) | + | + | + | + | + | -- | -- |
2. Vaccine Priorities, NVS and guidelines | |||||||||||
Phase I | ++ | -(+) | ++ | -(+) | N/R | N/R | + | -- | + | ++ | -(+) |
Phase II | ++ | ++ | ++ | ++ | N/R | N/R | -- | -- | -- | ++ | ++ |
Phase III | + | + | + | + | N/R | N/R | + | + | + | + | + |
3. Supply and procurement strategies | |||||||||||
Phase I | +(+) | N/R | +(+) | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
Phase II | +(+) | N/R | +(+) | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
Phase III | + | N/R | + | N/R | N/R | N/R | N/R | N/R | N/R | N/R | N/R |
4. Country eligibility and program filters | |||||||||||
Phase I | + | +(+) | + | +(+) | +(+) | +(+) | -- | -- | -- | -- | -- |
Phase II | +(+) | +(+) | +(+) | +(+) | +(+) | +(+) | -- | -- | -- | -- | -- |
Phase III | +(+) | +(+) | +(+) | +(+) | +(+) | +(+) | -- | -- | -- | -- | -- |
5. Large countries and budget cap policies | |||||||||||
Phase I | N/R | N/R | N/R | N/R | -- | -- | -(+) | -- | -- | -- | -- |
Phase II | N/R | N/R | N/R | N/R | -- | -- | -(+) | -- | -- | -- | -- |
Phase III | N/R + N/A | N/R + N/A | N/R + N/A | N/R + N/A | N/R + N/A | N/A | N/A | N/A | N/A | N/A | N/A |
6. Cash-based support and guidelines | |||||||||||
Phase I | N/R | N/A | N/R | N/A | -- | -- | -(+) | -- | -- | -- | -- |
Phase II | N/R | N/A | N/R | N/A | -- | -- | +(+) | +(+) | -- | -- | -- |
Phase III | N/R | N/A | N/R | N/A | -- | -- | + | + | + | -- | -- |
7. Vaccine introduction grants (VIGs) policies | |||||||||||
Phase I | N/R | N/A | N/R | N/A | -- | -- | -- | -- | -- | -- | -- |
Phase II | N/R | N/A | N/R | N/A | -- | -- | -- | -- | -- | -- | -- |
Phase III | N/R | N/A | N/R | N/A | -- | -- | -- | -- | -- | -- | -- |
8. Financial sustainability (Co-financing) | |||||||||||
Phase I | N/R | -- | N/R | -- | N/R | N/R | -- | -- | -- | -- | -- |
Phase II | N/R | + | N/R | + | N/R | N/R | -- | -- | -- | -- | -- |
Phase III | N/R | + | N/R | + | N/R | N/R | -- | -- | -- | -- | -- |
9. ‘Fragile States’ policies | |||||||||||
Phase I | -- | -(+) | -- | -(+) | -- | -- | -- | -- | -- | -- | -- |
Phase II | -- | -- | -- | -- | -- | -- | + | -- | -- | -- | -- |
Phase III | + | + | + | + | + | + | + | + | + | + | -- |
10. Gender Policy | |||||||||||
Phase I | N/R + N/A | N/A | N/R + N/A | N/A | N/R + N/A | N/A | N/A | N/A | N/A | N/R + N/A | N/A |
Phase II | N/R | N/R | N/R | N/R | -- | -- | N/R | N/R | + | -- | -- |
Phase III | N/R | N/R | N/R | N/R | -- | -- | N/R | N/R | + | -- | -- |
11. Programme prioritization | |||||||||||
Phase I | N/R + N/A | N/A | N/R + N/A | N/A | N/R + N/A | N/A | N/A | N/A | N/A | N/R + N/A | N/A |
Phase II | N/R + N/A | N/A | N/R + N/A | N/A | N/R + N/A | N/A | N/A | N/A | N/A | N/R + N/A | N/A |
Phase III | N/R | -- | N/R | -- | N/R | -- | -- | -- | -- | N/R | -- |